The developed nanoplatform can be used to track glioma cells (as well as other tumor cells with a high level of transferrin receptors (TfR) expression) by MRI, magnetic particle quantification (MPQ) [38,39,40], or optical methods, and additionally supplemented with a therapeutic agent for targeted delivery to malignant glioma cells. Here, TFRC is linked to malignant glioma.